Niacin is also known as vitamin B3, Nicotinic Acid, and has two additional forms, Niacinamide (Nicotinamide) and Inositol Hexanicotinate. It is an organic compound and normally included as one of the 80 essential human nutrients.
You will find Niacin in a number of multivitamins, energy drinks like Red Bull, 5 Hour Energy and Monster and it is also a common component of nootropic stacks.
While Niacin is not the most powerful cognitive enhancer available, it is known to improve mental energy, focus and alertness. The popular nootropic supplement Picamilon breaks down into Niacin and GABA when it reaches your brain.
Niacin is also one of the 5 vitamins that, when lacking in the human diet, is associated with a pandemic deficiency disease (pellagra). The supplement has also been used for over 50 years to help increase levels of HDL (the ‘good’ cholesterol) in the blood. It has also been found to decrease the risk of cardiovascular events.
Niacin is a colorless and water-soluble solid vitamin. It is derived from pyridine and normally used to help convert food into fuel and energy. This supplement is also useful in helping the body use fats and proteins, as well as helping the nervous system to function properly.
There is also evidence suggesting that Niacin (along with additional B-complex vitamins) are needed for healthy skin, hair, eyes, and liver. Niacin also assists in the synthesis of various sex and stress related hormones, primarily in the adrenal glands. It also helps to improve circulation.



- Helps maintain healthy cholesterol levels
- Supports proper metabolic functioning
- Promotes heart & nervous system health
Why is Niacin in Energy Drinks?
Related Topics
Niacin is commonly found in energy drink such as Red Bull. It is also widely used as a pre-workout supplement, but it is not a typical stimulant.
Niacin works through a series of complex biological and mechanical processes within the body.
While it is not a direct precursor of Nicotinamide, both substances are actually precursors to NAD and NADP. These (NAD and NADP) are vital in a number of hydrogen transfer processes in the body including the catabolism of fat, carbohydrate, protein, alcohol.
It is interesting to note that Niacin actually binds to and stimulates a specific type of protein, known as GPR109A. This protein causes the inhibition of fat breakdown in adipose tissue. As a result of blocking this process it causes a decrease in free fatty acids in the blood, which decreases liver secretions of cholesterol (lowering LDL levels).
It is also critically important in cell signaling and DNA repair. Whenever there is a deficiency in any of these supplements or substances, high energy requirement organs like the brain and high turnover rate organs such as the gut and skin are most at risk.
Furthermore, Niacin is a cerebral vasodilator, increasing blood flow to the brain. This has the effect of supplying your brain cells with more oxygen and glucose which can then be used to make ATP – the primary energy currency of the brain.
As a vasodilator, Niacin also helps to flush out toxins and improves the removal of waste products from your neurons. This ensures that your brain cells are functioning at optimal levels and are properly maintained with the necessary nutrients.
Niacin is also vital in the production of steroid hormones, especially within the adrenal gland.
Niacin Benefits for Energy & Brain Function
One of the most important and well-known benefits (and uses) of Niacin supplementation is lowering elevated LDL (bad) cholesterol levels.
This works best in individuals who have elevated levels; the supplement does not seem to be particularly effective if LDL levels are already fairly close to normal. When using Niacin for this purpose it is also important to carefully follow the recommended dosage guidelines.
There is some evidence to suggest that Niacin may be beneficial in helping to fight against atherosclerosis and heart disease. One study indicates that taking Niacin in combination with Colestipol helps to slow down the progression of atherosclerosis in people with heart disease (they also had fewer heart attacks and deaths).
Another study combined Niacin with Zocor. The results indicated that this supplement combination can help to lower the risk of having a first heart attack or stroke. Even taking Niacin alone has been shown to reduce the risk of heart attacks, especially second heart attacks.
There are also some interesting effects of Niacin upon Diabetes. Type I Diabetes is a condition where the immune system targets and attacks cells in the pancreas that make insulin, eventually destroying them. Niacin has been shown to help protect these cells, at least for a time.
This supplement also is known to help reduce fats and cholesterol levels in the body, which can be beneficial for those with Type II Diabetes. However, it may also raise blood sugar levels, so be sure to check with your doctor.
The most promising nootropic benefits of Niacin are related to mental energy, motivation, and concentration.
By increasing energy output in the brain, Niacin can have a positive effect on overall cognitive performance. This supplement may help you stay focused for long periods of time and combat fatigue during draining tasks. Niacin also has some neuroprotective benefits that can improve the health of your neurons and supporting cells.
Niacin Dosage
The dosage recommendations for Niacin are all over the map depend upon the purpose of supplementation in the first place.
For example, a child suffering from Niacin deficiency would be directed to take up to 16 mg per day. On the other hand, an adult suffering from the same thing would probably be using 50 to 100 mg three to four times a day.
Generally, however, one should never take more than 500 mg of Niacin in a single day. It is strongly advised that new users start off with the lowest effective dose, which might mean beginning in the range of 10 to 25 mg per day. The dosage may be split into several different administrations throughout the day, as well.
As a nootropic, more people will use Picamilon for their Niacin supply instead of taking Niacin itself. This has to do with how nutrients are transported across the blood-brain barrier. Picamilon is known for targeting the brain more efficiently and therefore can lead to a greater magnitude of cognitive benefits.
Picamilon is essentially a supplement made of the neurotransmitter GABA combined with Niacin. When it enters into the Central Nervous System, it is broken down into these constituents and has a mood enhancing effect, known to reduce anxiety levels while also being somewhat stimulating.
Side Effects & Dangers
There are some side effects which have been associated with Niacin usage. The most common of these is called the Niacin ‘flush,’ which includes a burning, tingling sensation in the face and chest, and red or flushed skin. The best way to help reduce or eliminate this is by taking an aspirin 30 minutes before the Niacin.
At higher doses (such as would likely be required to fight high cholesterol and other conditions) this may lead to stomach ulcers and possible liver damage. People with a history of kidney disease, stomach ulcers, and liver disease should avoid Niacin supplementation.
User Reviews
Niacin, or Vitamin B3, is a supplement that can offer significant benefits if used properly. You consume Niacin on a daily basis in many common foods and energy-boosting produces like Red Bull. Even though it is not the strongest nootropic you can buy today, it does do a good job of complementing other nootropics to improve focus, alertness and energy.
If you are planning to use a particularly high dosage of this supplement, pay attention to the warnings and consult with a doctor first, if you have Diabetes, kidney, or liver issues.
- Wierzbicki AS, Viljoen A. Fibrates and niacin: is there a place for them in clinical practice? Expert Opin Pharmacother. 2014
- Scholz K, Kynast AM, Couturier A, Mooren FC, Krüger K, Most E, Eder K, Ringseis R. Supplementing healthy rats with a high-niacin dose has no effect on muscle fiber distribution and muscle metabolic phenotype. Eur J Nutr. 2014
- HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014
- Boden WE, Sidhu MS, Toth PP. The therapeutic role of niacin in dyslipidemia management. J Cardiovasc Pharmacol Ther. 2014
- Bregar U, Jug B, Keber I, Cevc M, Sebestjen M. Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction. Heart Vessels. 2014
- Heemskerk MM, van den Berg SA, Pronk AC, van Klinken JB, Boon MR, Havekes LM, Rensen PC, van Dijk KW, van Harmelen V. Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B. Am J Physiol Endocrinol Metab. 2014
- Ganji SH, Kukes GD, Lambrecht N, Kashyap ML, Kamanna VS. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2014
- Zambon A, Zhao XQ, Brown BG, Brunzell JD. Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Am J Cardiol. 2014
- He YM, Feng L, Huo DM, Yang ZH, Liao YH. Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis. Int Urol Nephrol. 2014
- Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, Barrett PH. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014
- Sahebkar A. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials. Vasc Med. 2014
- Si Y, Zhang Y, Zhao J, Guo S, Zhai L, Yao S, Sang H, Yang N, Song G, Gu J, Qin S. Niacin inhibits vascular inflammation via downregulating nuclear transcription factor-κB signaling pathway. Mediators Inflamm. 2014
- Couturier A, Keller J, Most E, Ringseis R, Eder K. Niacin in pharmacological doses alters microRNA expression in skeletal muscle of obese Zucker rats. PLoS One. 2014
- Ginsberg HN, Reyes-Soffer G. Niacin: a long history, but a questionable future. Curr Opin Lipidol. 2013
- [No authors listed] New thinking on niacin use. Using niacin to raise good" cholesterol doesn't lower your risk of having a heart attack or stroke." Harv Health Lett. 2014
- Khan M, Couturier A, Kubens JF, Most E, Mooren FC, Krüger K, Ringseis R, Eder K. Niacin supplementation induces type II to type I muscle fiber transition in skeletal muscle of sheep. Acta Vet Scand. 2013
- Song WL, FitzGerald GA. Niacin, an old drug with a new twist. J Lipid Res. 2013
- Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE; AIM-HIGH Investigators. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke. 2013
- Khan M, Ringseis R, Mooren FC, Krüger K, Most E, Eder K. Niacin supplementation increases the number of oxidative type I fibers in skeletal muscle of growing pigs. BMC Vet Res. 2013
- Chauke CG, Arieff Z, Kaur M, Seier JV. Effects of short-term niacin treatment on plasma lipoprotein concentrations in African green monkeys (Chlorocebus aethiops). Lab Anim (NY). 2014
- Scoffone HM, Krajewski M, Zorca S, Bereal-Williams C, Littel P, Seamon C, Mendelsohn L, Footman E, Abi-Jaoudeh N, Sachdev V, Machado RF, Cuttica M, Shamburek R, Cannon RO 3rd, Remaley A, Minniti CP, Kato GJ. Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels. Am J Cardiol. 2013
- van den Oever IA, Nurmohamed MT, Lems WF. Niacin for reduction of cardiovascular risk. N Engl J Med. 2014
- Kamanna VS, Ganji SH, Kashyap ML. Recent advances in niacin and lipid metabolism. Curr Opin Lipidol. 2013
- Chaffman MO, Webster WB, Winiecki JT. Efficacy and safety evaluation of a large niacin therapeutic interchange program. Ann Pharmacother. 2013
- Hamoud S, Kaplan M, Meilin E, Hassan A, Torgovicky R, Cohen R, Hayek T. Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol. Am J Med Sci. 2013
- McCarthy M. Niacin fails to reduce vascular events in large randomised trial. BMJ. 2014
- Parson HK, Harati H, Cooper D, Vinik AI. Role of prostaglandin D2 and the autonomic nervous system in niacin-induced flushing. J Diabetes. 2013
- Terakata M, Fukuwatari T, Kadota E, Sano M, Kanai M, Nakamura T, Funakoshi H, Shibata K. The niacin required for optimum growth can be synthesized from L-tryptophan in growing mice lacking tryptophan-2,3-dioxygenase. J Nutr. 2013
- Lloyd-Jones DM. Niacin and HDL cholesterol--time to face facts. N Engl J Med. 2014
- Sazonov V, Maccubbin D, Sisk CM, Canner PL. Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. Int J Clin Pract. 2013
- Philpott AC, Hubacek J, Sun YC, Hillard D, Anderson TJ. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy. Atherosclerosis. 2013
- Mayer L. Niacin for reduction of cardiovascular risk. N Engl J Med. 2014
- Wanders D, Graff EC, White BD, Judd RL. Niacin increases adiponectin and decreases adipose tissue inflammation in high fat diet-fed mice. PLoS One. 2013
- Gouni-Berthold I, Berthold HK. The role of niacin in lipid-lowering treatment: are we aiming too high? Curr Pharm Des. 2013
- Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013
- Nelson RH, Vlazny D, Smailovic A, Miles JM. Intravenous niacin acutely improves the efficiency of dietary fat storage in lean and obese humans. Diabetes. 2012
- Terakata M, Fukuwatari T, Sano M, Nakao N, Sasaki R, Fukuoka S, Shibata K. Establishment of true niacin deficiency in quinolinic acid phosphoribosyltransferase knockout mice. J Nutr. 2012
- Usman MH, Qamar A, Gadi R, Lilly S, Goel H, Hampson J, Mucksavage ML, Nathanson GA, Rader DJ, Dunbar RL. Extended-release niacin acutely suppresses postprandial triglyceridemia. Am J Med. 2012
- Ringseis R, Rosenbaum S, Gessner DK, Herges L, Kubens JF, Mooren FC, Krüger K, Eder K. Supplementing obese Zucker rats with niacin induces the transition of glycolytic to oxidative skeletal muscle fibers. J Nutr. 2013
- Crook MA. The importance of recognizing pellagra (niacin deficiency) as it still occurs. Nutrition. 2014
- Christou GA, Rizos EC, Mpechlioulis A, Penzo C, Pacchioni A, Nikas DN. Confronting the residual cardiovascular risk beyond statins: the role of fibrates, omega-3 fatty acids, or niacin, in diabetic patients. Curr Pharm Des. 2014
- Steinhagen-Thiessen E, Dänschel W, Buffleben C, Smolka W, Pittrow D, Hildemann SK. Extended-release niacin/laropiprant for lipid management: observational study in clinical practice. Int J Clin Pract. 2013
- Huang PH, Lin CP, Wang CH, Chiang CH, Tsai HY, Chen JS, Lin FY, Leu HB, Wu TC, Chen JW, Lin SJ. Niacin improves ischemia-induced neovascularization in diabetic mice by enhancement of endothelial progenitor cell functions independent of changes in plasma lipids. Angiogenesis. 2012
- Creider JC, Hegele RA, Joy TR. Niacin: another look at an underutilized lipid-lowering medication. Nat Rev Endocrinol. 2012
- Gomaraschi M, Ossoli A, Adorni MP, Damonte E, Niesor E, Veglia F, Franceschini G, Benghozi R, Calabresi L. Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome. Vascul Pharmacol. 2015
- Ganji SH, Kashyap ML, Kamanna VS. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. Metabolism. 2015
- Keenan JM. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate no-flush" niacin in persons with mild to moderate dyslipidemia." J Clin Lipidol. 2013
- Jones KW. Do patients on statins also need niacin? JAAPA. 2013
- Lauring B, Taggart AK, Tata JR, Dunbar R, Caro L, Cheng K, Chin J, Colletti SL, Cote J, Khalilieh S, Liu J, Luo WL, Maclean AA, Peterson LB, Polis AB, Sirah W, Wu TJ, Liu X, Jin L, Wu K, Boatman PD, Semple G, et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med. 2012
- Mason CM, Doneen AL. Niacin-a critical component to the management of atherosclerosis: contemporary management of dyslipidemia to prevent, reduce, or reverse atherosclerotic cardiovascular disease. J Cardiovasc Nurs. 2012
- Viljoen M, Swanepoel A, Bipath P. Antidepressants may lead to a decrease in niacin and NAD in patients with poor dietary intake. Med Hypotheses. 2015
- MacKay D, Hathcock J, Guarneri E. Niacin: chemical forms, bioavailability, and health effects. Nutr Rev. 2012
- Yadav R, France M, Younis N, Hama S, Ammori BJ, Kwok S, Soran H. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety. Expert Opin Pharmacother. 2012
- Zhou E, Li Y, Yao M, Wei Z, Fu Y, Yang Z. Niacin attenuates the production of pro-inflammatory cytokines in LPS-induced mouse alveolar macrophages by HCA2 dependent mechanisms. Int Immunopharmacol. 2014
- Tofield A. Niacin and statin intolerable for some people. Eur Heart J. 2013
- Zhang LH, Kamanna VS, Ganji SH, Xiong XM, Kashyap ML. Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells. J Lipid Res. 2012
- Xu XJ, Jiang GS. Niacin-respondent subset of schizophrenia â€" a therapeutic review. Eur Rev Med Pharmacol Sci. 2015
- Streja E, Kovesdy CP, Streja DA, Moradi H, Kalantar-Zadeh K, Kashyap ML. Niacin and Progression of CKD. Am J Kidney Dis. 2015
- Messamore E. Niacin subsensitivity is associated with functional impairment in schizophrenia. Schizophr Res. 2012
- Taylor JK, Plaisance EP, Mahurin AJ, Mestek ML, Moncada-Jimenez J, Grandjean PW. Paraoxonase responses to exercise and niacin therapy in men with metabolic syndrome. Redox Rep. 2015
- Hughes-Large JM, Pang DK, Robson DL, Chan P, Toma J, Borradaile NM. Niacin receptor activation improves human microvascular endothelial cell angiogenic function during lipotoxicity. Atherosclerosis. 2014
- Heemskerk MM, Dharuri HK, van den Berg SA, Jónasdóttir HS, Kloos DP, Giera M, van Dijk KW, van Harmelen V. Prolonged niacin treatment leads to increased adipose tissue PUFA synthesis and anti-inflammatory lipid and oxylipin plasma profile. J Lipid Res. 2014
- Jackevicius CA, Tu JV, Ko DT, de Leon N, Krumholz HM. Use of niacin in the United States and Canada. JAMA Intern Med. 2013
- Blaha MJ, Michos ED. Niacin--a case study for the role of event-driven versus surrogate endpoint trials. Heart. 2013
- Khera AV, Patel PJ, Reilly MP, Rader DJ. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol. 2013
- Lim GB. Atherosclerosis: Addition of niacin to optimal statin therapy does not affect plaque regression. Nat Rev Cardiol. 2013
- Digby JE, Ruparelia N, Choudhury RP. Niacin in cardiovascular disease: recent preclinical and clinical developments. Arterioscler Thromb Vasc Biol. 2012
- Michos ED, Sibley CT, Baer JT, Blaha MJ, Blumenthal RS. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoin... J Am Coll Cardiol. 2012
- Wu BJ, Chen K, Barter PJ, Rye KA. Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation. 2012
- Jacobson EL, Kim H, Kim M, Jacobson MK. Niacin: vitamin and antidyslipidemic drug. Subcell Biochem. 2012
- Bassan M. A case for immediate-release niacin. Heart Lung. 2012
- Villines TC, Kim AS, Gore RS, Taylor AJ. Niacin: the evidence, clinical use, and future directions. Curr Atheroscler Rep. 2012
- AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011
- Lavie CJ, Dinicolantonio JJ, Milani RV, O'Keefe JH. Niacin therapy lives for another day-maybe? J Am Coll Cardiol. 2013
- Lee SJ, Roh MR, Lee SH, Chung WS, Lee JE, Oh SH, Cho SB. Topical niacin cream-assisted 595-nm pulsed-dye laser treatment for facial flushing: retrospective analysis of 25 Korean patients. J Eur Acad Dermatol Venereol. 2012
- Drummond PD, Lazaroo D. The effect of niacin on facial blood flow in people with an elevated fear of negative evaluation. Eur Neuropsychopharmacol. 2012
- Domanico D, Verboschi F, Altimari S, Zompatori L, Vingolo EM. Ocular Effects of Niacin: A Review of the Literature. Med Hypothesis Discov Innov Ophthalmol. 2015
- Hochholzer W, Berg DD, Giugliano RP. The facts behind niacin. Ther Adv Cardiovasc Dis. 2011
- Ng CF, Lee CP, Ho AL, Lee VW. Effect of niacin on erectile function in men suffering erectile dysfunction and dyslipidemia. J Sex Med. 2011
- Ali AH, Mundi M, Koutsari C, Bernlohr DA, Jensen MD. Adipose Tissue Free Fatty Acid Storage in vivo - Effects of Insulin versus Niacin as a Control for Suppression of Lipolysis. Diabetes. 2015
- Döger MM, Sokmen BB, Yanardag R. Combined effects of niacin and chromium treatment on heart of hyperlipidemic rats. Hum Exp Toxicol. 2011
- Koh Y, Bidstrup H, Nichols DL. Niacin increased glucose, insulin, and C-peptide levels in sedentary nondiabetic postmenopausal women. Int J Womens Health. 2014
- Mani P, Rohatgi A. Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct? Curr Atheroscler Rep. 2015
Article last updated on: June 4th, 2018 by Nootriment
1 Comment
I am just beginning to experience the wonders of Niacin. Other research has led me to want to try L-Tyrosine and 5-HTP in a 10:1 dosage. I’m wondering if anyone has experience taking L-Tyrosine, 5-HTP, and higher dose (1-3g/day) Niacin at the same time. I would love to hear your experience, good or bad, with this. :)